Platelet Adhesion Test by Rotating Glass Bottle Method: Principle, Procedure, and Applications

The platelet adhesion test performed by the rotating glass bottle method is a well-established in vitro assay used to quantify the tendency of platelets to adhere to artificial surfaces, providing essential data for the hemocompatibility evaluation of blood-contacting medical devices and biomaterials. By comparing platelet counts before and after controlled rotational contact between anticoagulated blood and a glass surface, the method yields a platelet adhesion rate that supports conformity assessment under frameworks such as ISO 10993-4 and GB/T 16886.4. This article describes the technical principle, applicable sample types, testing items, procedural workflow, typical applications, and frequently asked questions related to this assay.

Technical Overview

The rotating glass bottle method is a classical platelet adhesion assay in which a defined volume of anticoagulated whole blood or platelet-rich plasma is placed inside a clean glass bottle and rotated at a constant low speed, typically 3 revolutions per minute, at physiological temperature (approximately 37 °C) for a fixed contact period, commonly 15 minutes. During rotation, a portion of the platelets in the blood sample adheres to the glass surface and is thereby removed from the circulating pool. Platelet counts are measured immediately before and after the rotation step, and the difference between the two values is used to calculate the platelet adhesion rate.

The fundamental principle of the assay is that platelets, upon contact with negatively charged or foreign surfaces such as glass, undergo activation, shape change, spreading, and irreversible adhesion. The extent of this adhesion reflects both the intrinsic adhesion capability of the platelets and the thrombogenic character of the contact surface. The platelet adhesion rate is calculated using the following expression:

Platelet adhesion rate (%) = (Platelet count before contact − Platelet count after contact) / Platelet count before contact × 100%

In biomaterials testing, the method is frequently applied within the thrombosis category of hemocompatibility evaluation described in ISO 10993-4 and its Chinese counterpart GB/T 16886.4. In this context, test materials are introduced into or coated onto the bottle interior, and the resulting adhesion rate is compared with that obtained on a reference surface such as untreated glass or an established control material. Lower platelet adhesion generally indicates improved blood compatibility, whereas markedly elevated adhesion suggests a thrombogenic surface.

In clinical laboratory practice, the same principle has historically been used to assess platelet function, because reduced adhesion may indicate disorders such as von Willebrand disease, Glanzmann thrombasthenia, or Bernard–Soulier syndrome, whereas elevated adhesion may be associated with prothrombotic states. Interpretation of results therefore depends on whether the assay is being used for material evaluation or for physiological assessment of a blood donor.

Testing Samples

Blood-Contacting Medical Devices

Samples derived from devices that contact circulating blood during clinical use are the primary candidates for this assay. Representative examples include:

• Intravascular catheters, cannulae, and introducer sheaths
• Extracorporeal circulation tubing, blood oxygenator components, and hemodialyzer membranes
• Blood collection, storage, and transfusion consumables
• Vascular grafts, stent surfaces, and other implantable blood-contacting components
• Perfusion and infusion sets intended for prolonged blood contact

Biomaterials and Surface Coatings

Material specimens such as polymer films, hydrophilic or antithrombotic coatings, hydrogels, metals, and ceramics can be evaluated by lining or placing the material inside the glass bottle so that the test surface is exposed to blood during rotation. Sample geometry should be standardized in terms of exposed surface area to allow valid comparison between materials and between test batches.

Biological Samples

The assay requires fresh anticoagulated blood, platelet-rich plasma, or washed platelet suspensions. Blood may be of human or animal origin (for example, rabbit, canine, ovine, or porcine), depending on the study design and the applicable biological evaluation plan. Sodium citrate is the preferred anticoagulant; EDTA is generally avoided because complete calcium chelation suppresses physiological adhesion behavior, and heparin may interfere with certain activation pathways depending on the protocol.

Testing Items

The core deliverables of the rotating glass bottle platelet adhesion test typically include the following:

• Baseline platelet count of the blood sample before surface contact
• Post-contact platelet count after the defined rotation period
• Platelet adhesion rate expressed as a percentage, calculated from the count difference
• Comparative results against reference or control surfaces tested in parallel
• Optional morphological examination of adherent platelets by scanning electron microscopy, including assessment of spreading, pseudopod extension, and aggregation
• Optional supplementary indices such as platelet activation markers, depending on the scope agreed in the test plan

For regulatory submissions, results are usually reported together with donor or animal blood source information, anticoagulant type, test conditions, replicate data, and acceptance criteria defined in the study protocol.

Testing Methods

A typical test workflow for the rotating glass bottle method comprises the following steps:

• Sample preparation: Glass bottles are cleaned and dried, and test materials are cut, mounted, or coated so that a defined surface area is exposed. Materials are equilibrated with physiological saline or phosphate-buffered solution where the protocol requires pre-conditioning.
• Blood collection and handling: Venous blood is drawn using a standardized technique, with the initial few drops discarded, and mixed gently with sodium citrate anticoagulant at a ratio of 9:1 (blood to anticoagulant). Testing is performed within the time window specified by the protocol, typically within two to four hours of collection, to preserve platelet reactivity.
• Baseline measurement: A platelet count of the well-mixed blood sample is performed before the rotation step, providing the pre-contact value.
• Contact and rotation: A measured aliquot of blood is transferred into the bottle, which is fixed to a rotating device and rotated at approximately 3 r/min for 15 minutes at 37 °C, ensuring continuous, gentle contact between blood and the test surface under controlled conditions.
• Post-contact measurement: After rotation, the blood is gently remixed and a second platelet count is performed, providing the post-contact value.
• Calculation and evaluation: The platelet adhesion rate is calculated from the two counts, and results from test surfaces are compared with control surfaces and, where applicable, with predefined acceptance limits.
• Quality control: Tests are commonly performed in triplicate, with negative and positive reference materials run in parallel, and complete blood counts verified to confirm that platelet values fall within physiologically acceptable ranges for the study.

Key technical precautions include avoiding vigorous mixing or traumatic venipuncture, which can cause pre-activation of platelets; minimizing the interval between collection and testing; controlling temperature and rotation speed precisely; and applying consistent counting methodology, whether by automated hematology analyzer or validated manual chamber counting. These measures reduce variability and ensure that the adhesion rate reflects genuine surface interaction rather than procedural artifacts.

Accredited third-party laboratories and in-house biological evaluation facilities generally conduct this assay under quality management systems aligned with ISO/IEC 17025, supporting the use of results in device registration dossiers and design verification files.

Applications

The rotating glass bottle platelet adhesion test serves a broad range of purposes across medical device development, materials research, and clinical laboratory diagnostics:

• Hemocompatibility evaluation of blood-contacting medical devices in support of ISO 10993-4 and GB/T 16886.4 biological evaluation, particularly for the thrombosis testing category
• Registration and regulatory submission support for market access in multiple jurisdictions, with testing performed by accredited third-party laboratories
• Research and development screening of surface modifications, including hydrophilic coatings, heparinized surfaces, zwitterionic modifications, and other antithrombotic treatments intended to reduce platelet adhesion
• Comparative material selection during device design, enabling ranking of candidate polymers, metals, and coatings before further in vivo evaluation
• Academic investigation of platelet–surface interactions, activation pathways, and the influence of surface charge, roughness, and wettability on thrombogenicity
• Clinical laboratory assessment of platelet adhesion function, contributing to the work-up of suspected platelet function disorders and inherited adhesion defects such as von Willebrand disease
• Supporting evaluation in pharmacological studies examining the effect of antiplatelet agents on adhesion behavior

FAQ

What is considered a normal or acceptable platelet adhesion rate?

For physiological assessment of healthy human donors, reported adhesion rates typically fall within an approximate range of 20% to 40%, although the exact reference interval depends on the laboratory protocol, counting method, and equipment. For biomaterial evaluation, there is no universal pass–fail limit; results are interpreted relative to control surfaces tested in parallel, with a negative control representing acceptable hemocompatibility and a positive control confirming the sensitivity of the assay.

Which anticoagulant should be used?

Sodium citrate is the recommended anticoagulant for this assay. EDTA is generally unsuitable because it fully chelates calcium and suppresses platelet adhesion, while heparin may alter activation behavior in some protocols. The blood-to-anticoagulant ratio and mixing procedure must be strictly controlled.

How does the rotating glass bottle method differ from other platelet adhesion techniques?

Compared with the glass bead column method, which exposes blood to a packed bed of beads under flow, the rotating bottle method applies gentle, uniform contact under low shear in a closed vessel. Compared with dynamic flow-chamber systems, it is simpler, highly reproducible, and well suited to screening, although it does not fully replicate physiological shear stress. The choice of method should follow the device's intended blood-contact conditions and the agreed test plan.

Which standards govern this test?

The assay is most commonly executed within the framework of ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) and the corresponding Chinese standard GB/T 16886.4. Where applicable, product-specific standards for infusion, transfusion, and extracorporeal equipment may also define relevant requirements.

What factors can affect the accuracy of results?

Major sources of variability include delayed testing after blood collection, traumatic venipuncture causing premature platelet activation, improper anticoagulation, inaccurate rotation speed or temperature, inconsistent sample surface area, and counting errors. Strict adherence to standardized procedures and the inclusion of controls mitigate these risks.

How should samples be submitted for testing?

Samples should be supplied in a clean, sterile condition representative of the finished product, with sufficient quantity for replicate testing and control comparisons. The test request should specify the material, surface to be evaluated, intended contact context, blood source preference (human or specified animal species), and any applicable acceptance criteria, allowing the laboratory to prepare a compliant test protocol.